3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
Specimen Handling
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Oxaliplatin
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
Leucovorin
2
IDRX-42
2
Folfox protocol
2
Endoscopy, Digestive System
2
Biopsy
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
s-formylglutathione hydrolase
1
repotrectinib
1
regorafenib
1
plecanatide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.